[Preliminary hemodynamic studies on the activity of meproscillarin (author's transl)].
In 10 patients with arterial hypertension and left heart failure the hemodynamic effect of 14-hydroxy-3-beta-[4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide (Ky 18, meproscillarin, Clift) was compared with placebo in a double-blind study. 15 min after oral administration of meproscillarin there was an increase of cardiac output and stroke volume by up to 25%. Heart rate, arterial blood pressure and left ventricular filling pressure remained unchanged.
D000368:Aged; D002301:Cardiac Glycosides / Q000494:pharmacology*; D004311:Double-Blind Method; D005260:Female; D006333:Heart Failure / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013997:Time Factors
D002301:Cardiac Glycosides; D010919:Placebos
Orientierende hämodynamische Untersuchungen über die Wirksamkeit von Meproscillarin.